ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Receives $31.05 Average PT from Analysts

Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) have received an average rating of “Moderate Buy” from the twenty brokerages that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, five have given a hold recommendation, thirteen have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $31.2105.

Several research analysts have recently commented on ACAD shares. UBS Group increased their price target on shares of ACADIA Pharmaceuticals from $35.00 to $40.00 and gave the stock a “buy” rating in a research note on Tuesday, January 6th. Oppenheimer reiterated a “market perform” rating on shares of ACADIA Pharmaceuticals in a report on Friday, February 6th. Wolfe Research started coverage on shares of ACADIA Pharmaceuticals in a research report on Monday, February 23rd. They set an “outperform” rating and a $33.00 target price on the stock. HC Wainwright restated a “buy” rating and set a $37.00 target price on shares of ACADIA Pharmaceuticals in a report on Tuesday, February 3rd. Finally, Royal Bank Of Canada reduced their price target on ACADIA Pharmaceuticals from $31.00 to $30.00 and set an “outperform” rating for the company in a research report on Thursday, February 26th.

Insider Buying and Selling at ACADIA Pharmaceuticals

In related news, EVP Jennifer J. Rhodes sold 6,950 shares of the business’s stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $23.38, for a total value of $162,491.00. Following the completion of the sale, the executive vice president directly owned 7,609 shares in the company, valued at approximately $177,898.42. The trade was a 47.74% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 26.50% of the company’s stock.

Hedge Funds Weigh In On ACADIA Pharmaceuticals

A number of institutional investors have recently modified their holdings of ACAD. Farther Finance Advisors LLC boosted its holdings in shares of ACADIA Pharmaceuticals by 67.5% during the 4th quarter. Farther Finance Advisors LLC now owns 958 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 386 shares during the period. Meeder Asset Management Inc. bought a new position in ACADIA Pharmaceuticals in the 4th quarter worth $26,000. Geneos Wealth Management Inc. raised its holdings in ACADIA Pharmaceuticals by 113.0% in the 3rd quarter. Geneos Wealth Management Inc. now owns 1,425 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 756 shares during the period. Smartleaf Asset Management LLC lifted its position in ACADIA Pharmaceuticals by 107.0% during the 3rd quarter. Smartleaf Asset Management LLC now owns 1,712 shares of the biopharmaceutical company’s stock worth $36,000 after acquiring an additional 885 shares during the last quarter. Finally, Transamerica Financial Advisors LLC lifted its position in ACADIA Pharmaceuticals by 304.5% during the 4th quarter. Transamerica Financial Advisors LLC now owns 1,335 shares of the biopharmaceutical company’s stock worth $36,000 after acquiring an additional 1,005 shares during the last quarter. Institutional investors own 96.71% of the company’s stock.

ACADIA Pharmaceuticals Price Performance

Shares of ACADIA Pharmaceuticals stock opened at $22.16 on Tuesday. The firm has a market cap of $3.78 billion, a price-to-earnings ratio of 9.68, a P/E/G ratio of 18.71 and a beta of 0.66. The stock has a 50-day simple moving average of $25.01 and a 200-day simple moving average of $24.36. ACADIA Pharmaceuticals has a 52-week low of $13.40 and a 52-week high of $28.35.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last released its quarterly earnings data on Thursday, February 26th. The biopharmaceutical company reported $1.60 EPS for the quarter, topping analysts’ consensus estimates of $0.12 by $1.48. The firm had revenue of $298.00 million for the quarter, compared to the consensus estimate of $292.54 million. ACADIA Pharmaceuticals had a return on equity of 12.49% and a net margin of 36.49%.The firm’s revenue was up 9.4% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.86 earnings per share. As a group, equities research analysts predict that ACADIA Pharmaceuticals will post 0.7 earnings per share for the current year.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA’s research centers concentrate on conditions with significant unmet medical needs, including Parkinson’s disease psychosis, Alzheimer’s disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.

The company’s flagship product, NUPLAZID® (pimavanserin), received U.S.